RU97112898A - 6- [Triazolyl- [3- (trifluoromethyl) phenyl] methyl] -2-quinolines and -quinolines - Google Patents
6- [Triazolyl- [3- (trifluoromethyl) phenyl] methyl] -2-quinolines and -quinolinesInfo
- Publication number
- RU97112898A RU97112898A RU97112898/04A RU97112898A RU97112898A RU 97112898 A RU97112898 A RU 97112898A RU 97112898/04 A RU97112898/04 A RU 97112898/04A RU 97112898 A RU97112898 A RU 97112898A RU 97112898 A RU97112898 A RU 97112898A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- methyl
- acid addition
- hydrogen
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000002253 acid Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical compound C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- FQBCVCYAAKRJGJ-UHFFFAOYSA-N 6-[1,2,4-triazol-1-yl-[3-(trifluoromethyl)phenyl]methyl]-1H-quinolin-2-one Chemical compound FC(F)(F)C1=CC=CC(C(C=2C=C3C=CC(=O)NC3=CC=2)N2N=CN=C2)=C1 FQBCVCYAAKRJGJ-UHFFFAOYSA-N 0.000 claims 1
- 229960005084 CALCITRIOL Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
- 229960001727 Tretinoin Drugs 0.000 claims 1
- 239000003377 acid catalyst Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 238000005576 amination reaction Methods 0.000 claims 1
- 235000020964 calcitriol Nutrition 0.000 claims 1
- 239000011612 calcitriol Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 230000003780 keratinization Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrugs Drugs 0.000 claims 1
- 239000003638 reducing agent Substances 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 CC(CCN1C(*)(C(C2)*(*)CC(C3N)=C2C=CC3=O)C2C=CC=*C2)*C1I Chemical compound CC(CCN1C(*)(C(C2)*(*)CC(C3N)=C2C=CC3=O)C2C=CC=*C2)*C1I 0.000 description 1
Claims (13)
его фармацевтически приемлемая кислотно-аддитивная соль или стереохимически изомерная форма,
где R1 представляет водород, амино или C1-4 алкил;
R2 представляет водород, галоген или C1-4 алкил;
R3 представляет водород, галоген или C1-4 алкил;
Y представляет О или S и
-Х1 =Х2 - представляет двухвалентный радикал, имеющий формулу
-N=CH- (а-1) или
-СН=N- (а-2).1. The compound of formula I
its pharmaceutically acceptable acid addition salt or stereochemically isomeric form,
where R 1 represents hydrogen, amino or C 1-4 alkyl;
R 2 represents hydrogen, halogen or C 1-4 alkyl;
R 3 represents hydrogen, halogen or C 1-4 alkyl;
Y represents O or S and
—X 1 = X 2 — represents a divalent radical having the formula
-N = CH- (a-1) or
-CH = N- (a-2).
где R2, R3 и -Х1=Х2- определяются как в п. 1, его кислотно-аддитивная соль или стереоизомерная форма.12. The intermediate product of formula II
where R 2 , R 3 and —X 1 = X 2 are defined as in claim 1, its acid addition salt or stereoisomeric form.
соединение указанной формулы I-b-1, где R2, R3 и -X1=X2- определяются как в п. 1, N-алкилируют реагентом С1-4алкил-L, где L-реакционноcпособная уходящая группа, получая таким образом соединение формулы I-b-2,
соединение указанной формулы I-b-1, где R2, R3 и -X1=X2- определяются как в п. 1, подвергают реакции с агентом аминирования, получая таким образом соединение формулы I-b-3
соединение формулы I-в
где R1, R2, R3 и -X1=X2- определяются как в п. 1, превращают при помощи известных в данной области превращений в соединение формулы I-c
соединение формулы IV-5
где R2 и -Х1=Х2- определяются как в п. 1, подвергают реакции с 1,2,4-триазолом или 1,3,4-триазолом в присутствии восстановителя и необязательно в присутствии кислотного катализатора для превращения в соединение формулы I-b-1-a
и затем, если необходимо, превращают соединение формулы (I) в кислотно-аддитивную соль обработкой подходящей кислотой или, наоборот, превращают кислотно-аддитивную соль в свободное основание обработкой щелочью; и/или получают его стереохимически изомерные формы.13. A method of producing a compound according to claim 1, characterized in that the nitron of the specified formula II, where R 2 , R 3 and —X 1 = X 2 - are defined as in claim 1, is reacted with a suitable ether-forming reagent or with a sulfonyl-containing electrophilic reagent or dissolved in an inert solvent in the reaction and irradiated, thereby obtaining a compound of formula Ib-1,
the compound of the specified formula Ib-1, where R 2 , R 3 and -X 1 = X 2 - are defined as in claim 1, N-alkylated with a reagent C 1-4 alkyl-L, where L is a reactive leaving group, thus obtaining the compound of formula Ib-2,
the compound of the specified formula Ib-1, where R 2 , R 3 and -X 1 = X 2- are defined as in claim 1, are reacted with an amination agent, thereby obtaining a compound of formula Ib-3
compound of formula Ib
where R 1 , R 2 , R 3 and —X 1 = X 2 - are defined as in claim 1, are converted using compounds known in the art into a compound of formula Ic
compound of formula IV-5
where R 2 and —X 1 = X 2 - are defined as in claim 1, are reacted with 1,2,4-triazole or 1,3,4-triazole in the presence of a reducing agent and optionally in the presence of an acid catalyst for conversion to a compound of the formula Ib-1-a
and then, if necessary, the compound of the formula (I) is converted into an acid addition salt by treatment with a suitable acid, or, conversely, the acid addition salt is converted into the free base by treatment with alkali; and / or receive its stereochemically isomeric forms.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94203773 | 1994-12-28 | ||
EP94203773.0 | 1994-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97112898A true RU97112898A (en) | 1999-06-27 |
RU2165419C2 RU2165419C2 (en) | 2001-04-20 |
Family
ID=8217501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97112898/04A RU2165419C2 (en) | 1994-12-28 | 1995-12-21 | 6 [triazolyl-[3-(trifluoromethyl)phenyl] nathyl]-2- quinolines and quinolinethiones, composition, and method of preparing thereof |
Country Status (25)
Country | Link |
---|---|
US (1) | US5922734A (en) |
EP (1) | EP0800524B1 (en) |
JP (1) | JPH10511654A (en) |
CN (1) | CN1085668C (en) |
AR (1) | AR002264A1 (en) |
AT (1) | ATE207924T1 (en) |
AU (1) | AU698199B2 (en) |
BR (1) | BR9510504A (en) |
CA (1) | CA2207268A1 (en) |
DE (1) | DE69523629T2 (en) |
DK (1) | DK0800524T3 (en) |
ES (1) | ES2166838T3 (en) |
FI (1) | FI972794A (en) |
HR (1) | HRP950616A2 (en) |
IL (1) | IL116577A (en) |
MY (1) | MY131690A (en) |
NO (1) | NO311220B1 (en) |
NZ (1) | NZ298789A (en) |
PL (1) | PL182956B1 (en) |
PT (1) | PT800524E (en) |
RU (1) | RU2165419C2 (en) |
TR (1) | TR199501688A2 (en) |
TW (1) | TW316902B (en) |
WO (1) | WO1996020200A1 (en) |
ZA (1) | ZA9510989B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
US6420555B1 (en) | 1998-06-16 | 2002-07-16 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Imidazolyl derivatives |
EP1097150B1 (en) * | 1998-06-16 | 2004-03-24 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Imidazolyl derivatives |
EP1420015A1 (en) * | 1999-06-11 | 2004-05-19 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Imidazolyl derivatives |
ATE434615T1 (en) * | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | FARNESYLTRANSFERASE INHIBITING BENZOHETROCYCLIC DERIVATIVES |
US20040044032A1 (en) * | 2000-11-28 | 2004-03-04 | End David William | Farnesyl protein transfer inhibitors for the treatment of inflammatory bowel disease |
DE60119383T2 (en) * | 2000-12-27 | 2007-04-19 | Janssen Pharmaceutica N.V. | FARNESYL TRANSFERASE-INHIBITING 4-HETEROCYCLYLCHINOLIN AND CHINAZOLINE DERIVATIVES |
WO2002051835A1 (en) * | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
US4859684A (en) * | 1986-09-15 | 1989-08-22 | Janssen Pharmaceutica N.V. | (1H-imidazol-1-ylmethyl) substituted benzimidazole derivatives and use thereof in treating androgen dependent disorders |
NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
CA2002859C (en) * | 1988-11-29 | 1998-12-29 | Jean P. F. Van Wauwe | Method of treating epithelial disorders |
CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
US5157046A (en) * | 1988-11-29 | 1992-10-20 | Janssen Pharmaceutica N.V. | Method of treating epithelial disorders |
US5185346A (en) * | 1988-11-29 | 1993-02-09 | Hanssen Pharmaceutica | (1H-azol-1-ylmethyl)substituted quinoline derivatives |
-
1995
- 1995-12-20 TW TW084113605A patent/TW316902B/zh active
- 1995-12-21 US US08/860,239 patent/US5922734A/en not_active Expired - Fee Related
- 1995-12-21 DE DE69523629T patent/DE69523629T2/en not_active Expired - Fee Related
- 1995-12-21 CA CA002207268A patent/CA2207268A1/en not_active Abandoned
- 1995-12-21 CN CN95197162A patent/CN1085668C/en not_active Expired - Fee Related
- 1995-12-21 NZ NZ298789A patent/NZ298789A/en unknown
- 1995-12-21 ES ES95943237T patent/ES2166838T3/en not_active Expired - Lifetime
- 1995-12-21 JP JP8520222A patent/JPH10511654A/en active Pending
- 1995-12-21 WO PCT/EP1995/005173 patent/WO1996020200A1/en not_active Application Discontinuation
- 1995-12-21 AT AT95943237T patent/ATE207924T1/en not_active IP Right Cessation
- 1995-12-21 PT PT95943237T patent/PT800524E/en unknown
- 1995-12-21 DK DK95943237T patent/DK0800524T3/en active
- 1995-12-21 EP EP95943237A patent/EP0800524B1/en not_active Expired - Lifetime
- 1995-12-21 RU RU97112898/04A patent/RU2165419C2/en not_active IP Right Cessation
- 1995-12-21 PL PL95321041A patent/PL182956B1/en unknown
- 1995-12-21 AU AU44362/96A patent/AU698199B2/en not_active Ceased
- 1995-12-21 BR BR9510504A patent/BR9510504A/en not_active Application Discontinuation
- 1995-12-22 HR HR94203773.0A patent/HRP950616A2/en not_active Application Discontinuation
- 1995-12-27 AR ARP950100795A patent/AR002264A1/en unknown
- 1995-12-27 IL IL11657795A patent/IL116577A/en not_active IP Right Cessation
- 1995-12-27 ZA ZA9510989A patent/ZA9510989B/en unknown
- 1995-12-27 TR TR95/01688A patent/TR199501688A2/en unknown
- 1995-12-28 MY MYPI95004141A patent/MY131690A/en unknown
-
1997
- 1997-06-27 NO NO19973029A patent/NO311220B1/en unknown
- 1997-06-27 FI FI972794A patent/FI972794A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8107217A1 (en) | Naphthyridine derivatives, processes for their preparation and pharmaceutical compositions containing them. | |
KR890011853A (en) | Substituted pyrrole, pyrazole and triazole angiotensin II antagonists | |
CA2377746A1 (en) | N-pyrazole a2a receptor agonists | |
RU97102153A (en) | ACYLIC DERIVATIVES OF AZOLONES ACTING AGAINST HELICOBACTER | |
ES8505364A1 (en) | ((4-(4-(4-Phenyl-1-piperazinyl)phenoxymethyl)-1,3-dioxolan-2-yl)methyl)-1H-imidazoles and 1H-1,2,4-triazoles. | |
RU97112898A (en) | 6- [Triazolyl- [3- (trifluoromethyl) phenyl] methyl] -2-quinolines and -quinolines | |
CA2061692A1 (en) | Ceramides; process for preparing the same and their use as cosmetic and skin pharmaceutical agents | |
RU2004106783A (en) | 4-AMINO-6-Phenylpyrrolo [2, 3] Pyrimidine Derivatives | |
RU2001114978A (en) | N-ARILAMIDES OF ANTANILIC ACID AND THIOANTRANILIC ACID | |
ATE73799T1 (en) | DERIVATIVES OF ((4-(4-(4-PHENYL-1PIPERAZINYL)PHENOXYMETHYL>-1,3-DIOXOLAN2YL>METHYL>-1H-IMIDAZOLE AND 1H-1,2,4-TRIAZOLE. | |
AU2019265022A1 (en) | KDM1A inhibitors for the treatment of disease | |
RU97100151A (en) | DERIVATIVES OF PIPERAZINE AS ANTAGONISTS 5HT1A | |
KR970704738A (en) | Anti-helicobacter urea and thiourea derivatives of azolones of anti-helicobacter agenesis | |
CA2375385A1 (en) | Propargyl phenyl ether a2a receptor agonists | |
PH25504A (en) | Novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides pharmaceutical composition containing said compound, method of use thereof | |
HUT40626A (en) | Process for producing new compounds of sceletal muscules relaxing activity and pharmaceutical compositions containing them as active agents | |
AU1939692A (en) | New triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
RU95110937A (en) | Quinoline and acrydine compounds, process for preparation thereof, pharmaceutical composition, and intermediates | |
HUT61540A (en) | Process for producing new pharmaceutical compositions comprising diphenylimidazole derivatives and their active ingredients | |
HUT56352A (en) | Process for producing imidazole guanidine derivatives and pharmaceutical compositions comprising same as active ingredient | |
RU2003130644A (en) | RARCARBOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AGAINST DIPRESSION AND FEAR | |
RU97115107A (en) | BICYCLIC DERIVATIVES OF ISOTHYOTURES USED IN THERAPY | |
KR960031442A (en) | Use of phenylcyclohexylcarboxamide | |
RU2001111812A (en) | TRICYCLIC delta 3-PIPERIDINES AS alpha <Mv> 2 <D> - ANTAGONISTS | |
MD1449F1 (en) | 2-Amino-1,2,3,4-tetrahydronaphthalene derivatives active on the cardiovascular system, process for their preparation and pharmaceutical compositions containing them |